CA
NZ
UK
AU
IND
US
Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 earnings of $0.47, beating consensus estimates of $0.34, with shares rising 6.6% in pre-market trading. This earnings beat is significant, as it demonstrates the company's ability to deliver on its clinical trials and grow its revenue. The …
Vir Biotechnology, Inc. (NASDAQ: VIR) reported earnings of $0.47 per share for the quarter ending June 30, 2026, significantly exceeding the consensus estimate of $0.34. The company’s market capitalization stands at around $1.5 billion, reflecting its growth potential in the competitive biotechnology sector. A …
This growth is largely driven by the company’s leading treatment, MIPLYFFA, which accounted for $30.2 million in sales during the quarter. The earnings per share (EPS) also surpassed consensus estimates, reported at $0.25 against an expected $0.11, reflecting not only operational success but also …
Paysign (NASDAQ: PAYS) reported second‑quarter revenue of $28.25 million, a 48.1% jump from a year earlier, while GAAP earnings per share rose to $0.11 versus the $0.06 consensus estimate. The surge was powered by an 88.9% increase in pharma revenue and a 21.4% lift …
Perrigo Company plc (NYSE: PRGO) delivered second-quarter earnings per share of $0.50 for the period ending June 27, 2026, topping analyst forecasts of $0.35. The company successfully managed to achieve this EPS outperformance amidst challenges posed by consumption trends which declined compared to last …
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) announced a second quarter loss of $-0.25 per share, missing analyst expectations by a narrow margin against a consensus estimate of $-0.24. The earnings reflect underlying challenges in the biotech sector as the company navigates a steep 24.5% decline …
Schrödinger Inc. has upgraded its revenue projection for 2026 to a range of $218 million to $228 million, marking a 5% increase compared to previous expectations. This adjustment comes as the company reports second-quarter results that saw annual contract value (ACV) reach $29.6 million, …
Solventum Corp (NYSE: SOLV) announced an adjusted earnings per share (EPS) of $2.55 for the second quarter of 2026, surpassing the consensus estimate of $1.94 significantly. The adjusted EPS reflects a remarkable 50.9% increase from the same period last year. With total sales reaching …
LivaNova reported second‑quarter revenue of $390.6 million, a 10.8% increase on a reported basis and 9.8% in constant‑currency terms, while earnings per share of $1.26 beat the $1.12 consensus. These upgrades reflect durable demand across its cardiopulmonary and neuromodulation segments and provide a clearer …
Merck KGaA's 2026 Q2 earnings call presentation has been released, providing investors with valuable insights into the company's performance and market trends in the healthcare sector. The presentation is a key event for investors, as it reveals the company's financials and operations for the …
Please wait processing your request...